Condition
Diffuse Large B Cell Lymphoma Relapsed clinical trials and research
Research outlook What's coming for Diffuse large B-cell lymphoma: the next 6 months to 5 yearsAs of November 12, 2026, Find a Trial lists 5 Diffuse Large B Cell Lymphoma Relapsed clinical trials that are recruiting, at sites in 5 countries (most in United States (3), Australia (1), Canada (1)). By phase: Phase 1 (3), Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 5Countries
Newest Diffuse Large B Cell Lymphoma Relapsed clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Radiation, Vancomycin, and CAR-T for B-Cell Lymphoma | Phase 1 | Philadelphia, Pennsylvania | Recruiting | Mar 18, 2026 |
| Ronde-cel versus standard CD19 CAR T‑cell therapy for relapsed or refractory large B‑cell lymphoma | Phase 3 | Gilbert, Arizona and 43 other locations | Recruiting | Sep 23, 2025 |
| Comparing advanced and classical immunotherapy for lymphoma treatment | — | Seoul and 1 other locations | Recruiting | Jan 28, 2025 |
| VK-2019 for adults with relapsed or refractory EBV-positive diffuse large B‑cell lymphoma | Phase 1 | Lexington, Kentucky | Recruiting | Jan 23, 2025 |
| Evaluating GF-CART01 for treating relapsed or refractory B-cell cancers | Phase 1 | Taipei | Recruiting | Nov 25, 2024 |
All recruiting trials (5)
-
Radiation, Vancomycin, and CAR-T for B-Cell Lymphoma
This trial tests if giving radiation and the antibiotic vancomycin before CAR-T cell therapy is feasible for adults with large B-cell lymphomas.
-
Ronde-cel versus standard CD19 CAR T‑cell therapy for relapsed or refractory large B‑cell lymphoma
This test sees if ronde-cel, a CAR T therapy that targets both CD19 and CD20, works better than currently used CD19 CAR T therapies for adults whose large B‑cell lymphoma returned or did not respond after first‑line treatment.
-
Comparing advanced and classical immunotherapy for lymphoma treatment
This study is testing whether newer immunotherapy treatments for high-grade B cell lymphoma work better and are safer than traditional methods for adults who have already had treatment that didn't work.
-
VK-2019 for adults with relapsed or refractory EBV-positive diffuse large B‑cell lymphoma
This trial tests daily oral VK-2019 in adults with relapsed or refractory EBV-positive DLBCL to see if it is safe and can control the disease.
-
Evaluating GF-CART01 for treating relapsed or refractory B-cell cancers
This study is testing a new CAR T cell therapy called GF-CART01 to see if it can help adults with tough-to-treat B-cell cancers that haven't responded to other treatments.
Related topics
Quick answers
How many Diffuse Large B Cell Lymphoma Relapsed clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 5 countries. The most sites are in United States (3 trials), Australia (1 trial), Canada (1 trial), South Korea (1 trial), Taiwan (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 3, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.